Laryngoscopy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Laryngoscopy is an endoscopic examination procedure used by ENT (ear, nose, and throat) surgeons, head and neck surgeons, and anaesthetists to visualise the larynx (voice box), vocal cords (true and false), epiglottis, arytenoids, subglottic airway, and hypopharynx. It is the primary investigation for any patient with persistent hoarseness, voice change, unexplained dysphagia, stridor, or a suspected laryngeal lesion. Two principal forms are in clinical use: flexible nasolaryngoscopy (FNL), performed in the outpatient clinic setting using a thin (3–4 mm diameter) fibreoptic or high-definition video nasolaryngoscope passed through the nostril with topical anaesthesia only — providing real-time views of the larynx during speech, swallowing, and breathing; and direct (rigid) laryngoscopy or microlaryngoscopy (MLS), performed under general anaesthesia in the operating theatre with a rigid Lindholm or Dedo laryngoscope suspended from a chest support to provide bimanual access to the larynx under magnification with an operating microscope (6–25x magnification), enabling diagnostic biopsy, surgical excision, and laser treatment of laryngeal pathology. The two techniques are complementary: FNL is the essential first-line investigation; MLS is the definitive therapeutic intervention once pathology is identified. Videostroboscopy — FNL combined with a strobe light synchronised to the vocal cord vibration frequency — creates a slow-motion optical illusion of vocal cord mucosal wave patterns, providing uniquely detailed assessment of mucosal lesion characteristics and is the gold standard for assessing professional voice users and subtle vocal cord pathology.

Laryngoscopy is indicated for a wide range of clinical presentations evaluated by ENT, voice, and head and neck teams. Persistent hoarseness lasting more than three weeks is the most common indication — both NICE NG12 (suspected cancer) and AAO-HNS guidelines mandate urgent laryngoscopic evaluation within 2 weeks for hoarseness of this duration in any patient with a smoking history or aged over 45. Additional indications include: unexplained dysphagia (difficulty swallowing) or odynophagia (pain on swallowing); chronic or unexplained cough and repeated throat-clearing; stridor (audible airway noise from laryngeal or subglottic obstruction); evaluation of vocal cord paralysis or paresis (unilateral or bilateral) from any cause; suspected laryngeal cancer (warranting urgent referral); recurrent respiratory papillomatosis (HPV-related laryngeal warts); subglottic stenosis from prior intubation, Wegener's granulomatosis, or idiopathic causes; and assessment of swallowing function using flexible endoscopic evaluation of swallowing (FEES — a specialist extension of FNL). Microlaryngoscopy is indicated specifically for: biopsy of suspicious laryngeal lesions to obtain histological diagnosis; excision of vocal cord benign lesions — polyps (most common in voice abuse and smokers), Reinke's oedema (polypoid degeneration), nodules (in singers and teachers), granulomas (from reflux or intubation), and retention cysts; laser treatment of recurrent respiratory papillomatosis; laser or endoscopic management of subglottic or tracheal stenosis; and difficult airway management by anaesthesiologists.

Flexible nasolaryngoscopy (FNL) requires only topical lidocaine 1–2% spray to the nostril and oropharynx for tolerability. The 3–4 mm diameter flexible scope — a fibreoptic or high-definition chip-on-tip video nasolaryngoscope — is passed through the more patent nostril along the floor of the nasal cavity, over the inferior turbinate, past the nasopharynx, and advanced to the level of the hypopharynx where the larynx is viewed in its entirety. The patient is asked to breathe quietly, then phonically with sustained vowel sounds ('eeee') to abduct and then adduct the vocal cords, and swallow during FEES protocols. The procedure takes 5–10 minutes and is well tolerated by most patients. Direct microlaryngoscopy (MLS) is performed under general anaesthesia in the operating theatre. The patient is positioned supine with neck extended (sniffing position, or Boyce-Jackson position with neck hyperextension). A padded Lindholm or Dedo suspension laryngoscope is introduced through the mouth past the epiglottis to expose the vocal cords and subglottis. The laryngoscope is suspended from a Mayo chest support to free both hands of the surgeon. An operating microscope (6–25x magnification) provides magnified binocular views of the vocal cord mucosa. For laser surgery, a CO2 laser (10,600 nm — wavelength optimally absorbed by water in superficial mucosa, providing precise ablation with 0.1–0.2 mm control) or KTP/pulsed dye laser (532/585 nm — vascular target for papillomatosis) is used through a micromanipulator attached to the microscope. Cold steel microsurgical instruments — microsuctioner, straight and curved scissors, cupped forceps — are used for fine anatomical dissection of vocal cord lesions. A CO2 laser microspot of 250–600 microns allows near-bloodless excision of lesions with a margin of 1–2 mm of normal mucosa. Vocal cord injection augmentation (Cymetra, Radiesse, hyaluronic acid) for vocal cord paralysis or paresis can be performed concurrently. Total MLS duration is 30–60 minutes for most diagnostic and excision procedures.

Flexible laryngoscopy provides rapid in-clinic diagnosis within minutes, enabling early detection of laryngeal cancer at a stage when cure rates are excellent: T1 (limited to one vocal cord) laryngeal cancer treated with primary CO2 laser microlaryngoscopy or radiotherapy achieves 5-year local control rates exceeding 90% and overall survival over 85%, without requiring laryngectomy. Immediate visual diagnosis of vocal cord paralysis identifies the cause and allows rapid appropriate investigation including CT chest to exclude an apical lung (Pancoast) or mediastinal lesion compressing the recurrent laryngeal nerve. Videostroboscopy during FNL assesses vocal cord mucosal wave patterns with high sensitivity for early mucosal lesions not apparent on standard white-light laryngoscopy, making it the investigation of choice for professional voice users. Microlaryngoscopic surgical excision of benign vocal cord lesions (polyps, nodules, Reinke's oedema) achieves definitive resolution in over 90% of cases with immediate voice improvement, avoiding the morbidity of open laryngeal surgery. Laser treatment of recurrent respiratory papillomatosis — an HPV 6 and 11-driven disease that can cause life-threatening airway obstruction — achieves disease control in 80–90% of patients at each MLS session, providing sustained airway patency. The addition of adjuvant intral esional cidofovir or bevacizumab injection at MLS extends inter-treatment intervals and reduces disease burden in aggressive papillomatosis. Video documentation of each laryngoscopic examination allows precise serial comparison and invaluable patient education.

Flexible laryngoscopy carries minimal risk. Transient nasal and throat discomfort during insertion is expected. Vasovagal reactions (lightheadedness, bradycardia) occur in approximately 1–2%, managed by scope removal and supine positioning. Epistaxis from nasal mucosa is very rare and self-limiting. Patients with a very sensitive gag reflex may not tolerate FNL without an additional oropharyngeal local anaesthetic spray. Direct microlaryngoscopy under general anaesthesia carries anaesthetic risks, dental or lip injury from laryngoscope blade insertion (dental guards protect teeth), and the specific risk of laser-related airway fire in an oxygen-enriched environment: CO2 laser procedures require a laser-resistant tracheal tube (Laserguard or aluminium-wrapped) and the lowest possible inspired oxygen concentration (FiO2 below 0.3) — fire precautions are mandatory. Laryngeal oedema causing post-operative stridor occurs in under 2% and is managed with intravenous dexamethasone and nebulised adrenaline; it may necessitate overnight observation. Temporary dysphonia (worsening hoarseness for 1–4 weeks) from vocal cord manipulation and post-operative mucosal oedema is universal and expected after microlaryngoscopy and should be distinguished from procedure failure or complications. Mucosal scarring leading to permanent voice change is the most significant long-term surgical risk; it results from over-aggressive excision into the vocal ligament and is minimised by phonomicrosurgical technique preserving the superficial lamina propria. Voice rest of 5–10 days post-operatively is essential to prevent haematoma formation and reduce scar risk. Laryngospasm at extubation occurs in under 1% and is managed with anaesthetic techniques including topical lignocaine to the cords before extubation.

Flexible laryngoscopy requires no recovery whatsoever — patients return to all normal activities including driving and work immediately after the procedure. After direct microlaryngoscopy under general anaesthesia, patients are observed in the day-surgery recovery area for 1–2 hours until they are fully awake, maintaining their airway, and have adequate swallow reflex return. Stridor or increased work of breathing prompts observation until resolved. Voice rest — complete avoidance of speaking, shouting, and whispering (which paradoxically strains the cords more than normal speech) — is advised for 3–7 days after excision of benign vocal cord lesions; 10–14 days for more extensive laser procedures. Patients are provided with a whiteboard or text-to-speech device for communication during voice rest. Cool fluids and soft foods manage throat soreness in the first 24–48 hours; normal diet is resumed within 24 hours. Anti-reflux medication (proton pump inhibitor, twice daily for 8–12 weeks) is prescribed to all MLS patients to protect healing laryngeal mucosa from pepsin-mediated laryngopharyngeal reflux damage. Regular analgesics (paracetamol, ibuprofen) manage throat discomfort. Most patients notice voice improvement within 1–2 weeks as mucosal oedema resolves; maximum voice quality improvement is achieved by 4–6 weeks after surgery. Speech and language therapy (SLT) post-operatively for professional voice users — singers, teachers, actors — provides voice rehabilitation and relapse prevention strategies. Follow-up flexible laryngoscopy assesses healing at 4–6 weeks post-surgery; any suspicious appearances prompt early repeat biopsy. Patients with laryngeal cancer on histology are fast-tracked to the head and neck multidisciplinary team meeting within 1 week of report.